Topiroxostat
Systematic (IUPAC) name | |
---|---|
4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile | |
Clinical data | |
Trade names | Topiloric, Uriadec |
Legal status |
|
Identifiers | |
CAS Number | 577778-58-6 |
ATC code | None |
PubChem | CID 5288320 |
ChemSpider | 4450517 |
Chemical data | |
Formula | C13H8N6 |
Molar mass | 248.24 g/mol |
| |
|
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]
References
- 1 2 "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan.
- ↑ Hosoya, Tatsuo; Ohno, Iwao; Nomura, Shinsuke; Hisatome, Ichiro; Uchida, Shunya; Fujimori, Shin; Yamamoto, Tetsuya; Hara, Shigeko (2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. doi:10.1007/s10157-014-0935-8.
|
|
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.